[
1. REDD WD, ZHOU JC, HATHORN KE, MCCARTY TR, BAZARBASHI AN, THOMPSON CC, et al. Prevalence and characteristics of gastrointestinal symptoms in patients with SARS-CoV-2 infection in the United States: A multicenter cohort study. Gastroenterology. 2020; 159(2): 765–7.10.1053/j.gastro.2020.04.045
]Search in Google Scholar
[
2. HAQUE M, SARTELLI M, MCKIMM J, ABU BAKAR M. Health care-associated infections – an overview. Infection and Drug Resistance. 2018;11:2321–33.10.2147/IDR.S177247
]Search in Google Scholar
[
3. BENTIVEGNA E, ALESSIO G, SPUNTARELLI V, LUCIANI M, SANTINO I, SIMMACO M, et al. Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection. American Journal of Infection Control. 2020;1–3.10.1016/j.ajic.2020.09.010
]Search in Google Scholar
[
4. ESNAL DE, ONTIYUELO CM, ROUCO MEN, CUSCO MA, FERRANDEZ M, HORCAJADA JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Review of Anti-infective Therapy. 2020;19(2):147–63.10.1080/14787210.2020.1813024
]Search in Google Scholar
[
5. FERREIRA EO, PENNA B, YATES EA. Should we be worried about Clostridioides difficile during the SARS-CoV2 pandemic? Frontiers in Microbiology. 2020;11.10.3389/fmicb.2020.581343
]Search in Google Scholar
[
6. BIGNARDI GE. Risk factors for Clostridium difficile infection. Journal of Hospital Infections. 1998;40:1–15.10.1016/S0195-6701(98)90019-6
]Search in Google Scholar
[
7. CALU V, TOMA EA, ENCIU O, MIRON A. Clostridium difficile infection and colorectal surgery: is there any risk? Medicina. 2019;55:683.
]Search in Google Scholar
[
8. RAWSON TM, MOORE LSP, ZHU N, RANGANATHAN N, SKOLIMOWSKA K, GILCHRIST M, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;3;71(9):2459–68.10.1093/cid/ciaa530719759632358954
]Search in Google Scholar
[
9. CROBACH MJT, PLANCHE T, ECKERT C, BARBUT F, TERVEER EM, DEKKERS OM, et al. European Society of Clinical Microbiology and infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(s4):s63-s81.10.1016/j.cmi.2016.03.01027460910
]Search in Google Scholar
[
10. European Centre for Disease Prevention and Control. European Surveillance of Clostridium difficile infections. Surveillance protocol version 2.2. Stockholm: ECDC. 2015.
]Search in Google Scholar
[
11. MCDONALD LC, GERDING DN, JOHNSON S, BAKKEN JS, CARROLL KC, COFFIN SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). CID. 2018;66(7):e1–e48.10.1093/cid/cix1085601898329462280
]Search in Google Scholar
[
12. GRANATA G, BARTOLONI A, CODELUPPI M, CONTADINI I, CRISTINI F, FANTONI M, et al. The burden of Clostridioides diffcile infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid). J. Clin. Med. 2020; 9:3855.
]Search in Google Scholar
[
13. SANDHU A, TILLOTSON G, POLISTICO J, SALIMNIA H, CRANIS M, MOSHOS J, et al. Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020. Emerging Infectious Diseases. 2020; 26:9.10.3201/eid2609.202126745407532441243
]Search in Google Scholar
[
14. LANGFORD BJ, SO M, RAYBARDHAN S, LEUNG V, WESTWOOD D, MACFADDEN DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020; 26:1622–9.10.1016/j.cmi.2020.07.016783207932711058
]Search in Google Scholar
